Approved in May 2022, tirzepatide (Mounjaro®) by Eli Lilly is a dual GIP/GLP-1 receptor agonist designed to address both glycemic control and weight management in Type 2 Diabetes (T2D). By activating both receptors, it significantly lowers HbA1c levels and promotes weight loss, outperforming traditional GLP-1 agonists in clinical trials. The SURPASS-4 study further demonstrated reduced mortality rates in T2D patients using tirzepatide compared to insulin glargine during the COVID-19 pandemic. Its dual-action mechanism presents a promising therapeutic option for patients with complex metabolic conditions .
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
